QLT, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies in the fields of ophthalmology and dermatology primarily in the United States, Canada, and Europe. Its approved products include Visudyne, a photosensitizer for the treatment of choroidal neovascularization; Eligard product line for prostate cancer; and Aczone, a dermatology product for the treatment of acne vulgaris. The company’s products under development consist of expansion of Visudyne therapy; Eligard 3.75-mg one-month product for the treatment of prostate cancer; Aczone for treating Rosacea; Octreotide Atrigel- three-month product for the treatment of the symptoms of acromegaly; GHRP-1-Atrigel one-month product, a formulation of growth hormone releasing peptide-1 for the treatment of malnutrition in end-stage renal disease patients on hemodialysis; and Risperidone Atrigel- three-month product for the treatment of schizophrenia. In addition, the company has rights to commercialize ForSight Newco II, Inc.’s proprietary ocular punctal plug drug delivery system. The company has collaborative agreements with Novartis Ophthalmics; Sanofi-Synthelabo, Inc.; Medigene AG; Astellas; Han All Pharmaceutical Co.; Key Oncologics; Luxembourg Pharmaceuticals, Ltd.; Mayne Pharma Pty, Ltd.; Ranbaxy Laboratories, Ltd.; Sanofi-Synthelabo, Inc.; and Tecnofarma International, Ltd. QLT was founded in 1981 and is headquartered in Vancouver, Canada.